Go Pro

Arcus Biosciences (RCUS) Stock Forecast & Price Target

Arcus Biosciences logo
$30.14 -0.20 (-0.66%)
As of 08/21/2026 03:58 PM Eastern

Arcus Biosciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
3
Buy
8

Based on 12 Wall Street analysts who have issued ratings for Arcus Biosciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 1 has given a sell rating, 3 have given a hold rating, and 8 have given a buy rating for RCUS.

Consensus Price Target

$37.80
25.41% Upside
According to the 12 analysts' twelve-month price targets for Arcus Biosciences, the average price target is $37.80. The highest price target for RCUS is $47.00, while the lowest price target for RCUS is $23.00. The average price target represents a forecasted upside of 25.41% from the current price of $30.14.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for RCUS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Arcus Biosciences and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RCUS Analyst Ratings Over Time

TypeCurrent Forecast
8/24/25 to 8/24/26
1 Month Ago
7/25/25 to 7/25/26
3 Months Ago
5/26/25 to 5/26/26
1 Year Ago
8/24/24 to 8/24/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$37.80$36.40$33.89$21.14
Forecasted Upside25.41% Upside28.12% Upside40.21% Upside101.19% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

RCUS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RCUS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Arcus Biosciences Stock vs. The Competition

TypeArcus BiosciencesHealthcare CompaniesBroader Market
Consensus Rating Score
2.58
2.30
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside25.41% Upside833.52% Upside12.34% Upside
News Sentiment Rating
Positive News

See Recent RCUS News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/10/2026
Morgan Stanley logo
Morgan Stanley
4 of 5 stars
Terence Flynn
Terence Flynn
5 of 5 stars
Set Target$23.00-19.75%
8/7/2026
Richard Law
5 of 5 stars
Reiterated RatingBuy$42.00+48.78%
8/6/2026
Wedbush logo
Wedbush
5 of 5 stars
Robert Driscoll
Robert Driscoll
5 of 5 stars
Boost TargetOutperform$41.00 ➝ $43.00+54.04%
8/6/2026Boost TargetEqual Weight$23.00 ➝ $26.00-5.72%
7/20/2026Boost TargetBuy$32.00 ➝ $45.00+63.88%
7/17/2026 Reiterated RatingSell (D-)
6/4/2026Initiated CoverageOutperform$46.00+83.43%
5/18/2026Initiated CoverageBuy$30.00 ➝ $35.00+46.94%
4/20/2026 Set Target$47.00+105.67%
3/5/2026Boost TargetBuy$44.00 ➝ $45.00+105.67%
I found Rolls-Royce at $2 - now I see the same setup again (Ad)

In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had written off. The stock climbed more than 1,100% over the next 3-4 years, with some subscribers reporting gains of $141,000, $272,000, or more. He believes a similar setup is forming now around what he calls the 'Energy Cube' - a compact nuclear system roughly the size of a shipping container, capable of powering up to 1,000 homes with no emissions, 24 hours a day. Bill Gates, Jeff Bezos, Google, and Microsoft have all backed companies in this space. The Nuclear Regulatory Commission is expected to issue a key approval as early as August - the first of its kind for this technology class in over a decade.tc pixel

Watch the full presentation before the NRC decision arrives
12/15/2025 Reiterated RatingBuy
11/28/2025Boost TargetNeutral$17.00 ➝ $26.00+0.95%
4/23/2025Lower TargetOverweight$29.00 ➝ $14.00+72.73%
10/3/2024 Reiterated RatingOverweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 08:24 AM ET.


RCUS Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Arcus Biosciences is $37.80, with a high forecast of $47.00 and a low forecast of $23.00.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There is currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RCUS shares.

According to analysts, Arcus Biosciences's stock has a predicted upside of 25.41% based on their 12-month stock forecasts.

Arcus Biosciences has been rated by research analysts at HC Wainwright, Lifesci Capital, Morgan Stanley, The Goldman Sachs Group, Wedbush, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Arcus Biosciences more than other "healthcare" companies. The consensus rating for Arcus Biosciences is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how RCUS compares to other companies.


This page (NYSE:RCUS) was last updated on 8/24/2026 by MarketBeat.com Staff.
From Our Partners